1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Renal Tubular Acidosis (RTA) - Pipeline Insight, 2020

Renal Tubular Acidosis (RTA) - Pipeline Insight, 2020

  • October 2020
  • 65 pages
  • ID: 5976737
  • Format: PDF
  • Delve Insight


Table of Contents

“Renal tubular acidosis (RTA) – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Renal tubular acidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Renal tubular acidosis Understanding

Renal tubular acidosis (RTA): Overview
Renal tubular acidosis (RTA) is a disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person’s blood to remain too acidic. Without proper treatment, chronic acidity of the blood leads to growth retardation, kidney stones, bone disease, chronic kidney disease, and possibly total kidney failure. The body’s cells use chemical reactions to carry out tasks such as turning food into energy and repairing tissue. These chemical reactions generate acids. Some acid in the blood is normal, but too much acid—acidosis—can disturb many bodily functions. Healthy kidneys help maintain acid-base balance by excreting acids into the urine and returning bicarbonate—an alkaline, or base, substance—to the blood. This reclaimed bicarbonate neutralizes much of the acid that is created when food is broken down in the body. The movement of substances like bicarbonate between the blood and structures in the kidneys is called transport.
Renal tubular acidosis (RTA) is usually asymptomatic. Severe electrolyte disturbances are rare but can be life threatening. Nephrolithiasis and nephrocalcinosis are possible, particularly with type 1 RTA.
Signs of ECF volume depletion may develop from urinary water loss accompanying electrolyte excretion in type 2 RTA.
People with type 1 or type 2 Renal tubular acidosis may show symptoms and signs of hypokalemia, including muscle weakness, hyporeflexia, and paralysis. Bony involvement (eg, bone pain and osteomalacia in adults and rickets in children) may occur in type 2 and sometimes in type 1 Renal tubular acidosis.
To diagnose Renal tubular acidosis, doctors check the acid-base balance in blood and urine samples. If the blood is more acidic than it should be and the urine less acidic than it should be, Renal tubular acidosis may be the reason, but additional information is needed to rule out other causes. If RTA is the reason, additional information about the sodium, potassium, and chloride levels in the urine and the potassium level in the blood will help identify which type of Renal tubular acidosis a person has.

• Varies by type
• Often alkali therapy
• Treatment of concomitant abnormalities related to potassium, calcium, and phosphate metabolism
Treatment consists of correction of pH and electrolyte balance with alkali therapy. Failure to treat Renal tubular acidosis in children slows growth. Alkaline agents such as sodium bicarbonate, potassium bicarbonate, or sodium citrate help achieve a relatively normal plasma bicarbonate concentration (22 to 24 mEq/L [22 to 24 mmol/L]). Potassium citrate can be substituted when persistent hypokalemia is present or, because sodium increases calcium excretion, when calcium calculi are present.
Vitamin D (eg, ergocalciferol 800 IU po once/day) and oral calcium supplements (elemental calcium 500 mg po tid, eg, as calcium carbonate, 1250 mg po tid) may also be needed to help reduce skeletal deformities resulting from osteomalacia or rickets.

Renal tubular acidosis Emerging Drugs Chapters
This segment of the Renal tubular acidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Renal tubular acidosis Emerging Drugs
• ADV7103: Advicenne
ADV7103 is an innovative prolonged-release granule combination of potassium citrate and potassium bicarbonate. In 2017, ADV7103 was granted orphan drug designation by the European Commission in the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood. ADV7103 is currently in Phase III clinical trials for this indication in Europe, the United States and Canada, and a marketing application for the drug candidate has been submitted for centralized European review.
Further product details are provided in the report……..

Renal tubular acidosis: Therapeutic Assessment
This segment of the report provides insights about the different Renal tubular acidosis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Renal tubular acidosis
There are approx. 5+ key companies which are developing the therapies for Renal tubular acidosis. The companies which have their Renal tubular acidosis drug candidates in the mid to advanced stage, i.e. phase III include, Advicenne etc.
report covers around 5+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Renal tubular acidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intramuscular
• Intravenous

• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Potassium compounds
• Electrolytes
• Citrates

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Renal tubular acidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Renal tubular acidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal tubular acidosis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Renal tubular acidosis R&D. The therapies under development are focused on novel approaches to treat/improve Renal tubular acidosis.
• Advicenne has continued to prepare the next phase of its development, namely the European launch of its lead drug candidate, ADV7103, in the treatment of a first indication, distal renal tubular acidosis (dRTA), planned for the beginning of 2021.
Renal tubular acidosis Report Insights
• Renal tubular acidosis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Renal tubular acidosis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Renal tubular acidosis drugs?
• How many Renal tubular acidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal tubular acidosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Renal tubular acidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal tubular acidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Advicenne

Key Products
• ADV7103

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Postoperative pain - Pipeline Insight, 2021

  • $ 2500
  • February 2021
  • 200 pages

“Postoperative pain - Pipeline Insight, 2021,” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Postoperative pain pipeline landscape. It covers the pipeline drug ...

  • World
  • Therapy
  • Analgesic
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on